RERE (Arginine-Glutamic Acid Dipeptide Repeats) is a protein-coding gene implicated in transcriptional regulation, apoptosis, and embryonic development. It belongs to the atrophin family and interacts with nuclear receptors, chromatin modifiers, and signaling pathways (e.g., Wnt/β-catenin and NF-κB). RERE plays critical roles in organogenesis, particularly in the nervous system, heart, and eyes. Mutations or deletions in RERE are linked to neurodevelopmental disorders, including autism, intellectual disability, and 1p36 deletion syndrome—a condition characterized by seizures, vision impairment, and cardiac defects.
RERE antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Research using these antibodies has revealed RERE's involvement in tumorigenesis, with altered expression observed in cancers like leukemia and hepatocellular carcinoma. Additionally, RERE antibodies help investigate its role as a potential biomarker or therapeutic target. Studies in zebrafish and mouse models, supported by antibody-based detection, demonstrate RERE's conservation across species and its non-redundant functions in development. Despite progress, mechanisms underlying RERE-related pathologies remain under exploration, driving ongoing demand for high-specificity antibodies to advance diagnostic and therapeutic strategies.